Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Parkinson's Disease
Interventions: RO7046015, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more

Conditions: Nutrition, Fatty Acids, Omega-3, Cognition, Resilience, Psychological, Psychology, Military
Interventions: Phospholipid-bound omega-3 supplement, Placebo supplement; Dietary Supplement
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Not listed
Enrollment: 555 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Fort Benning, Georgia • Bethesda, Maryland • Charleston, South Carolina

Conditions: Social Anxiety Disorder
Interventions: Attention Disengagement Training (ADT), Placebo Condition; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Adults
Interventions: Body-Brain Trainer, Body Trainer, Brain Trainer, Expectancy Matched Control; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Blood Loss, Surgical
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Persistent Asthma
Interventions: Beclomethasone Dipropionate 640, Placebo, Beclomethasone dipropionate via 320 mcg BAI, albuterol/salbutamol, Beclomethasone dipropionate via 320 mcg MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 75
States / cities: Peoria, Arizona • Downey, California • Huntington Beach, California + 59 more

Conditions: MPS IV A
Interventions: BMN 110 Weekly, Placebo, BMN 110 Every Other Week; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 5 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 3 more

Conditions: Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions: Reltecimod 0.5 mg/kg, Placebo; Drug
Lead sponsor: Atox Bio Ltd; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more

Conditions: Recreational Drug Use
Interventions: PF614, Oxycodone Hydrochloride 40 mg, Placebo; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution; Drug
Lead sponsor: Aires Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV-1-infection
Interventions: SAR441236, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Conditions: Urea Cycle Disorders
Interventions: HPN-100, Buphenyl (NaPBA); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Stanford, California + 18 more

Conditions: Surgery, Sedation
Interventions: Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PTSD
Interventions: Glecaprevir/pibrentasvir, Placebo; Drug · Other
Lead sponsor: White River Junction Veterans Affairs Medical Center; Federal
Eligibility: 19 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: White River Junction, Vermont

Conditions: Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions: Naproxen Sodium, Placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
Interventions: dapagliflozin, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: Mobile, Alabama • Los Angeles, California • Pasadena, California + 11 more

Conditions: Gastroesophageal Reflux, Apnea, Bradycardia
Interventions: Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W); Drug · Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Days and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Stroke, Chronic Stroke, Upper Extremity Paresis, Ischemic Stroke, Hemorrhagic Stroke
Interventions: Active Vagus Nerve Stimulation, Placebo Vagus Nerve Stimulation; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 22 Years to 79 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions: Famotidine, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Minute to 12 Months
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Propionic Acidemia, Type I and/or Type II, Methylmalonic Acidemia, Carbamoyl-Phosphate Synthase I Deficiency Disease, Ornithine Carbamoyltransferase Deficiency
Interventions: Carbaglu, Placebo; Drug
Lead sponsor: Mendel Tuchman; Other
Eligibility: 1 Week to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more

Conditions: Acute Spinal Cord Injury
Interventions: SUN13837 injection, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 40
States / cities: Tucson, Arizona • Downey, California • Los Angeles, California + 32 more

Conditions: Opioid Withdrawal, Chronic Pain
Interventions: Buprenorphine Patch, Placebo, Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS); Drug · Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress Disorder
Interventions: BXCL501 (dexmedetomidine HCl), Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 3
States / cities: Jacksonville, Florida • St Louis, Missouri • Charlottesville, Virginia

Search by objective public record fields.

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's

Attention Disengagement Training for Social Phobia

Characterizing the Synergistic Effects of Physical and Cognitive Training on Attention and Working Memory

Role of TXA in Patients Undergoing Breast Free Flap Reconstruction

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

Pharmacokinetics and Safety of SAR441236

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Oral Versus Intravenous Sedation for Ocular Procedures

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

Mechanistic Characterization of Uterine Pain

Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Study of Erythromycin in GER-Associated Apnea of the Newborn

Wireless Nerve Stimulation Device To Enhance Recovery After Stroke

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

BXCL501 After Stress to Increase Recovery Success